Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Investment analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Galectin Therapeutics in a research report issued on Monday, November 16th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings per share of ($0.26) for the year, up from their prior forecast of ($0.30). The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q4 2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.16) EPS.
A number of other equities research analysts also recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Galectin Therapeutics in a report on Monday, September 14th. Zacks Research raised Galectin Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Galectin Therapeutics presently has an average rating of "Hold" and an average target price of $11.00.
Check Out Our Latest Report on GALT
Galectin Therapeutics Trading Down 3.6%
NASDAQ:GALT opened at $2.91 on Wednesday. Galectin Therapeutics has a 12-month low of $2.03 and a 12-month high of $7.13. The firm has a market cap of $191.65 million, a price-to-earnings ratio of -8.56 and a beta of 0.53. The company's 50-day moving average is $3.59 and its two-hundred day moving average is $3.22.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01.
Institutional Trading of Galectin Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its stake in Galectin Therapeutics by 101.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,001 shares of the company's stock valued at $31,000 after purchasing an additional 4,027 shares during the period. Argyle Capital Partners LLC bought a new position in Galectin Therapeutics in the 2nd quarter worth about $62,000. Archer Investment Corp acquired a new stake in shares of Galectin Therapeutics in the second quarter valued at approximately $81,000. Bank of America Corp DE increased its stake in shares of Galectin Therapeutics by 114.9% in the first quarter. Bank of America Corp DE now owns 53,862 shares of the company's stock valued at $150,000 after purchasing an additional 28,799 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in shares of Galectin Therapeutics by 13.1% in the third quarter. Commonwealth Equity Services LLC now owns 460,296 shares of the company's stock valued at $1,786,000 after purchasing an additional 53,183 shares during the period. Institutional investors and hedge funds own 11.68% of the company's stock.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company's research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer. Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.